These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24045678)

  • 41. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women.
    Weber L; Thacker HL
    Womens Health (Lond); 2014 Mar; 10(2):147-54. PubMed ID: 24601805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
    Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
    Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized, double-blind, placebo-controlled trial of Chinese herbal medicine granules for the treatment of menopausal symptoms by stages.
    Fu SF; Zhao YQ; Ren M; Zhang JH; Wang YF; Han LF; Chang YX; Fan GW; Wang H; Huang YH; Zhai JB; Dong JY; Li X; Ai JQ; Zhang H; Zhu Y; Zhang BL; Sun LK; Fan X; Gao XM
    Menopause; 2016 Mar; 23(3):311-23. PubMed ID: 26671188
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause.
    Pinkerton JV; Simon J; Panay N; Seitz C; Parke S; Caetano C; Mellinger U; Haseli Mashhadi N; Haberland C; Atanackovic G; Holz C; Mao G; Morrison M; Nisius S; Schaefers M; Zuurman L
    Menopause; 2024 Jun; 31(6):522-529. PubMed ID: 38564691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial.
    Tucker P; Zaninelli R; Yehuda R; Ruggiero L; Dillingham K; Pitts CD
    J Clin Psychiatry; 2001 Nov; 62(11):860-8. PubMed ID: 11775045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identifying meaningful differences in vasomotor symptoms among menopausal women.
    Wyrwich KW; Spratt DI; Gass M; Yu H; Bobula JD
    Menopause; 2008; 15(4 Pt 1):698-705. PubMed ID: 18369313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of controlled-release paroxetine in the treatment of late-life depression.
    Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD
    J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.
    Seedat S; Stein MB
    J Clin Psychiatry; 2004 Feb; 65(2):244-8. PubMed ID: 15003080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women.
    Stubbs C; Mattingly L; Crawford SA; Wickersham EA; Brockhaus JL; McCarthy LH
    J Okla State Med Assoc; 2017 May; 110(5):272-274. PubMed ID: 28649145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
    Archer DF; Seidman L; Constantine GD; Pickar JH; Olivier S
    Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
    Johnson KA; Martin N; Nappi RE; Neal-Perry G; Shapiro M; Stute P; Thurston RC; Wolfman W; English M; Franklin C; Lee M; Santoro N
    J Clin Endocrinol Metab; 2023 Jul; 108(8):1981-1997. PubMed ID: 36734148
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
    Rowan JP; Simon JA; Speroff L; Ellman H
    Clin Ther; 2006 Jun; 28(6):921-32. PubMed ID: 16860174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).
    Ruan X; Bai W; Ren M; Kim T; Lee JY; Chuang FC; Wang PH; He W; Ma X; Miyazaki K; Song N; Wang X; Yu Q
    J Int Med Res; 2024 May; 52(5):3000605241247684. PubMed ID: 38818888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paroxetine in the treatment of dysthymic disorder without co-morbidities: A double-blind, placebo-controlled, flexible-dose study.
    Ravindran AV; Cameron C; Bhatla R; Ravindran LN; da Silva TL
    Asian J Psychiatr; 2013 Apr; 6(2):157-61. PubMed ID: 23466114
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study.
    Stein DJ; Versiani M; Hair T; Kumar R
    Arch Gen Psychiatry; 2002 Dec; 59(12):1111-8. PubMed ID: 12470127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
    Guthrie KA; LaCroix AZ; Ensrud KE; Joffe H; Newton KM; Reed SD; Caan B; Carpenter JS; Cohen LS; Freeman EW; Larson JC; Manson JE; Rexrode K; Skaar TC; Sternfeld B; Anderson GL
    Obstet Gynecol; 2015 Aug; 126(2):413-422. PubMed ID: 26241433
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: a double-blind, placebo-controlled study.
    Garcia JT; Gonzaga F; Tan D; Ng TY; Oei PL; Chan CW
    Menopause; 2010 Mar; 17(2):303-8. PubMed ID: 19934777
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of citalopram and venlafaxine's role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial.
    Davari-Tanha F; Soleymani-Farsani M; Asadi M; Shariat M; Shirazi M; Hadizadeh H
    Arch Gynecol Obstet; 2016 May; 293(5):1007-13. PubMed ID: 26437957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.